secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269481
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Medical Q3 rev +11% to $50.2M; slashes FY2025 guidance to $211-213M
--------------------------------------------------------------------------

- Revenue $50.2M (+11% YoY); net loss $(16.3)M or $(0.26)/share vs $(15.4)M loss in Q3 2024.
- Adjusted EBITDA loss narrowed 49% to $(2.6)M from $(5.1)M in Q3 2024.
- FY2025 revenue guidance cut to $211-213M (prev $224-230M); Adj. EBITDA loss now $6.5-7.5M (prev breakeven).
- CEO cites headwinds from shift to MIS procedures, softer consumer demand, and macroeconomic conditions impacting Lapiplasty.
- Director Richard W. Mott retired Nov 3; Board reduced to 7 members.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000119312525269481/0001193125-25-269481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000119312525269481/tmci-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer